C ardiac implantable electronic devices (CIEDs) can improve clinical outcomes in selected patients with heart failure and reduced ejection fraction (HFrEF) and can also collect valuable diagnostic information via continuous monitoring of several physiological variables. This information allows for assessment to determine signs of volume overload and to predict the onset of HF exacerbation, as well as monitoring the effects of any particular treatment. [1] Variables that are readily accessible from routine device interrogation include intrathoracic impedance (ITI), patient activity (PA), and heart rate variability (HRV).
The PARADIGM-HF trial demonstrated that sacubitril/valsartan treatment significantly reduced the primary endpoints of cardiovascular mortality, HF hospitalization, and all-cause mortality in patients with symptomatic HFrEF c o m p a r e d with enalapril. [2] Since then, sacubitril/valsartan has been recommended in current guidelines as foundational therapy for patients with s y m p t o m a t i c HFrEF. [3] However, the temporal relationship between sacubitril/valsartan treatment and Diagnostic -More diagnostics -Counters event, change in drug therapy, or adverse drug reaction related with sacubitril/valsartan treatment during the 6-month period. Current treatment was continued without any alteration and another visit was scheduled for 6 months later.
DISCUSSION
Dual inhibition of the renin-angiotensin-aldosterone system and neprilysin represent a novel approach to treating patients with HFrEF. The PARADIGM-HF trial demonstrated the superiority of sacubitril/valsartan to enalapril in hard outcomes (death from any cause and death from cardiovascular causes). [2] In their 2016 focused update on HF guidelines, the American College of Cardiology (ACC), the American Heart Association (AHA), and the Heart Failure Society of America (HFSA) recommended replacing an angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blocker (ARB) with an angiotensin receptor-neprilysin inhibitor (ARNI) in patients with chronic symptomatic HFrEF, New York Heart Association class II or III, currently tolerating an ACEI or ARB, to further reduce morbidity and mortality (class I recommendation). [3] On the other hand, the 2016 European Society of Cardiology (ESC) HF guidelines recommend the use of sacubitril/valsartan as an ACEI replacement to further reduce the risk of death and HF hospitalization in ambulatory patients with HFrEF (LVEF <35%) who remain symptomatic despite optimal treatment with ACEI, a beta-blocker, and a mineralocorticoid receptor antagonist (MRA) (class IB recommendation). [4] In contrast to ACC/AHA/HFSA guidelines, the ESC guidelines specify having an LVEF cut-off of 35% prior to initiation of sacubitril/valsartan, initial treatment with an MRA, and the patient should have elevated natriuretic peptide levels (i.e., plasma brain natriuretic peptide [BNP] ≥150 pg/mL) before initiating use of an ARNI. [4] ARNI treatment was initiated in this patient based on the ACC/AHA/HFSA guidelines, despite a BNP value that was below to ESC guideline cut-off. The PARADIGM Trial also demonstrated the greater effectiveness of ARNIs compared with enalapril with respect to physical capacity and symptoms and quality of life, which was measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ). [2] Although previous studies have proven the validity of the KCCQ score in the HFrEF population, it has limitations, such as the absence of appropriate reference standards for the various domains, and patient perspective (subjectivity). The score also has a vulnerability in terms of physician-originated bias. Researchers and many physicians often rely on physiological variables, such as LVEF or N-terminal pro-BNP levels to monitor therapy in HFrEF population. However, such surrogate markers may not always be as useful as expected, due to lower temporal resolution and vulnerability to confounding factors.
CIEDs include remote monitoring tools intended to guide heart failure management. These tools allow for daily observation of particular physiological functions. [2] They are objective measurements with high temporal resolution that permit analysis of trends. In this case, the patient's self-reported improvements in symptoms and PA level were objectively confirmed by CIED monitoring functions. To the best of our knowledge, this is the first case documenting improvements in ITI, PA, and HRV levels with sacubitril/valsartan treatment using CIED reporting. These hypothesis-generating findings provide the rationale for further study focused on the effects of sacubitril/ valsartan treatment in HFrEF patients who have a CIED. The CHILISALT Study (Changes in Intrathoracic Impedance during Sacubitril/Valsartan Treatment; NCT03359967) will be 1 study to obtain more information in this patient population.
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